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Background: Medicine price information mechanisms provide an essential tool to countries that seek a better
understanding of product availability, market prices and price compositions of individual medicines. To be effective
and contribute to cost savings, these mechanisms need to consider prices in their particular contexts when
comparing between countries. This article discusses in what ways medicine price information mechanisms can
contribute to increased price transparency and how this may affect access to medicines for developing countries.
Methods: We used data collected during the course of a WHO project focusing on the development of a vaccine
price and procurement information mechanism. The project collected information from six medicine price
information mechanisms and interviewed data managers and technical experts on key aspects as well as observed
market effects of these mechanisms.
The reviewed mechanisms were broken down into categories including objective and target audience, as well as
the sources, types and volumes of data included. Information provided by the mechanisms was reviewed according
to data available on medicine prices, product characteristics, and procurement modalities.
Results: We found indications of positive effects on access to medicines resulting from the utilization of the
reviewed mechanisms. These include the uptake of higher quality medicines, more favorable results from contract
negotiations, changes in national pricing policies, and the decrease of prices in certain segments for countries
participating in or deriving data from the various mechanisms.
Conclusion: The reviewed mechanisms avoid the methodological challenges observed for medicine price
comparisons that only use national price databases. They work with high quality data and display prices in the
appropriate context of procurement modalities as well as the peculiarities of purchasing countries. Medicine price
information mechanisms respond to the need for increased medicine price transparency and have the potential to
contribute to improved access to medicines in developing countries.
Additional research is required to explore more specific aspects. These include the market effects of dedicated
donor funds for certain medicines to explain the driving force of user demands, and the effects of increased price
transparency on different groups of medicines in context of the maturity of their markets.
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Opinions diverge about the effects of improved price
transparency in medicine markets. There is some debate
as to whether increased price transparency would have
more positive or negative effects on the availability and
affordability of medicines [1].
Medicine price information mechanisms are significant
tools to achieve increased price transparency by provid-
ing information on product prices as well as the compo-
nents that influence these prices, such as volume and
product quality. Information provided by such mecha-
nisms allows developing countriesa to make more in-
formed decisions about the most efficient and effective
ways to procure medicines. In addition to providing
comparative price information between market partici-
pants, which would be challenging to access in similar
quality for individual countries without such tools, medi-
cine price information mechanisms can help identify
and improve inefficiencies in existing procurement sys-
tems when providing contextual information about the
reported prices.
Cost reductions through improved efficiencies have the
potential to create more effective public health systems in
developing countries, where the pricing of medicines is a
critical factor in accessing treatment. This article takes a
closer look at the pros and cons of increased medicine
price transparency with regards to access to medicines in
developing countries and assesses the role of medicine
price information mechanisms in this context.
It is important to note that any comparison of medicine
prices will only produce significant results when taking
into account the quality aspect and comparing products
of same and similar effect. Unregulated, mislabeled or de-
liberately counterfeited pharmaceutical products pose a
significant problem not only to procurement agencies
but also to the safety of patients. Therefore it is im-
portant to limit the comparison of medicine prices to
generic products that are considered identical ‘to a brand
name drug in dosage form, safety, strength, route of
administration, quality, performance characteristics and
intended use [2]’.
Medicine prices and access to health care in developing
countries
There are various factors influencing the access to medi-
cines for the public sector, including the availability of
sustainable financing, reliable health systems, rational se-
lection and use of medicines, as well as affordable pricing
[3]. Medicine prices form one important aspect determin-
ing access to affordable health care in developing countries,
where systems are often not able to provide sufficient
appropriate treatment and care. Patients frequently need to
pay for medication as part of public sector treatment or
are required to purchase medicines in the private sectordue to low availability in the public health system [4].
These payments can be significant. WHO statistics reveal
that in 32 percent of the Low and Lower middle income
countriesb private expenses constitute more than half of
the total health spending [5]. Furthermore, statistics show
that ‘in countries where patients pay for medicines in the
public sector, average prices of generic medicines range
from 1.9 to 3.5 times international reference prices’ be-
tween different WHO regions [6].
Price differences between regions and countries de-
pend on a variety of factors and need to be understood
in their respective context. WHO identifies some of the
contributing factors as shortcomings in public procure-
ment systems, insufficient financing of public health care
systems and other policy related issues [6]. Lower medi-
cine prices can be achieved by addressing some of the
inefficiencies through strategies such as bulk purchasing,
increased competition, skillful negotiation and thorough
supply management [7].
Increased transparency of medicine prices can have a
positive impact on the application of such strategies for
countries that have not reached their full potential in
achieving appropriate prices and fully efficient procure-
ment systems.
Medicine price components
The meaningful comparison of international medicine
prices requires an understanding of the various compo-
nents constituting a price. In addition to varying market
conditions for individual medicines, such as ease of mar-
ket access and level of competition, specific procurement
conditions can have additional effects on prices. Among
other factors, these can include volumes purchased, the
terms of delivery (Incoterms) applying to a contracted
price and the currency of the purchase agreement. Con-
tracts may also include specific conditions such as bund-
ling or special discounts [4].
While some purchase agreements are made directly
with medicine suppliers and manufacturers, others are
made through procurement agents, local import agents,
wholesalers or distributors whose mark-ups need to be
taken into account as well. Manufacturer prices are
often kept confidential [4], therefore conducting reli-
able and useful medicine price comparisons can be
challenging for countries without appropriate skills
and access to additional information. Morgan et al. [8]
note several disadvantages of confidential rebate agree-
ments between countries and pharmaceutical compan-
ies, such as increased administrative costs and a loss of
transparency which makes it more difficult to obtain
comparative price information. They advise policy makers
to achieve more transparent prices and contract structures
in order to address disproportionate price differences
within and between countries.
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In 2001, the World Health Assembly passed Resolution
WHA 54.11, outlining the WHO medicines strategy [9].
The resolution focused on the expansion of access to es-
sential drugs and the promotion of equitable access to
medicines. In addition to other aspects, the resolution
called for action to increase medicine price transparency
by exploring ‘the feasibility and effectiveness of imple-
menting, in collaboration with nongovernmental organiza-
tions and other concerned partners, systems for voluntary
monitoring drug prices and reporting global drug prices
with a view to improving equity in access to essential drugs
in health systems, and to provide support to Member
States in that regard’ [9].
In the years following the resolution, various medicine
price information mechanisms were instituted, including
five of those described in this paper, targeted primarily
at developing countries and with the aim of increasing
price transparency.
Effects of increased price transparency
Increased price transparency can have various effects on
the medicine market. In competitive markets, economic
theory predicts a decrease and convergence of prices as a
consequence of improved transparency. Measures under-
taken in high income countries to increase price transpar-
ency in private medicine markets have produced this
effect [10].
There is only a small amount of evidence of the net
effects of price transparency in developing country markets
[1]. However, advocates of increased price transparency
highlight potential cost savings through better informed
procurement agents and efficiency improvements for estab-
lished procurement systems [4]. The availability of com-
parative pricing information from other buyers allows
purchasing countries to leverage their negotiation pos-
ition and demand more favorable prices for their pur-
chases [1]. Improvements in efficiency can result from
reduced search costs [11] and from benchmarking na-
tional medicine prices against the results achieved by
other countries. Exploring the effects of increased price
transparency of medical devices, Pauly and Burns [12]
note how comparing the procurement results of different
hospitals can help improve the performance of staff. Simi-
lar effects can be expected for the performance of national
procurement agencies.
However, these effects do not necessarily translate into
cost savings or other effects that may result in increased
access to medicines for developing countries. As Hviid
and Møllgaard [13] show, medicine suppliers may adapt
their price strategies to the improved knowledge of buyers
and refrain from offering lower prices or individual dis-
counts to countries. Critics point out that this can lead
to a convergence of prices to a more uniform level. Inequitable pricing scenarios, this could jeopardize the bene-
fits the poorest countries might derive from price discrim-
ination as they would eventually need to pay more for
their medicines if prices became more uniform [14].
Other potential negative effects of price transparency in-
clude possible harmful consequences for medicine manu-
facturers that could also affect the availability of medicines
in developing countries. As Outterson [15] notes, critics
maintain that reduced medicine prices due to increased
price transparency could harm profits to an extent that
companies may consider withdrawing their product from
the market or reducing their investment in the develop-
ment of new drugs specific to the needs of developing
countries. Pauly [16] indicates that profit maximizing
companies invest in research and development based on
the expected demand and value of a product that makes it
reasonable to incur such a financial risk. However, should
profits fall below a certain margin, such investments may
indeed be cancelled. There may also be the risk of market
exit of companies whose cost structure cannot compete
with more efficient competitors, which in turn could
negatively affect developing countries’ access to medicines.
Different effects of increased transparency can be ex-
pected in markets with different stages of maturity. For
example, in less mature oligopolistic markets, which would
be a characteristic of innovative medicines, given demand
for a product in the absence of an abundance of suppliers
will result in high prices. However, as Møllgaard and Over-
gaard [17] note, varying market behavior of suppliers and
buyers can lead to different outcomes. While increased
price transparency could provide incentives for collusion
between suppliers and therefore drive prices up, transpar-
ency can also lead to increased competition, provided that
market behavior of buyers has previously been constricted
due to limited information.
It could therefore be acknowledged that increased
price transparency can trigger both positive and negative
consequences for a developing country’s access to medi-
cines. As noted by Møllgaard and Overgaard [17] re-
garding market effects of increased price transparency in
oligopolies, ‘the effect of information or transparency
needs to be assessed on a case-by-case basis’. Additional
research and a more detailed analysis on the net costs or
benefits of increased medicine price transparency will be
necessary to identify the specific effects in various
market scenarios with different levels of maturity.
Medicine price information mechanisms
Van Dongen [18] conducted a review of 50 national and
21 international price sources, and provided an overview
of the availability of medicine price information as well
as an evaluation of the reported information. Her ana-
lysis came to the conclusion that despite the wide availabil-
ity of medicine price information websites large variations
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identical productsc. Prior to the establishment of most of
the mechanisms reviewed, Danzon and Chao [19] showed
that earlier comparisons of medicine prices between coun-
tries were not methodologically sound. Unrepresentative
sampling and different approaches in the collection of
national drug prices resulted in limited comparability
between different data sets. The misinterpretation of data
could therefore have led to wrong conclusions that did not
allow for improvements of existing national procurement
strategies.
Comparability of prices between countries is often lim-
ited due to differences in procurement modalities and
supply chain systems. Additional factors may be in place
that make a market particularly attractive for medicine
suppliers (e.g. market size and disease burden) or allow
a country access to prices attributable to donor support
(e.g. per capita income). Other barriers affecting the
correct interpretation of data exist, such as differences
in reporting languages. However, van Dongen [18] also
identified significant price discrepancies between ra-
ther similar countries, indicating considerable oppor-
tunities for further improvements.
From a methodological point of view, van Dongen’s
study [18] concluded that international price compari-
sons are best conducted utilizing mechanisms that con-
tain price information from multiple countries. This is
considered to be less time consuming and error-prone
than retrieving data from multiple national websites which
may apply different methodologies for data collection [18].
Information provided about the procurement systems and
procedures used to achieve individual prices further
contributes to meaningful results of price comparisons.
Methods
Original research was conducted for the World Health
Organization’s (WHO) Vaccine Product, Price and Pro-
curement (V3P) project [20]. The V3P project intends to
address the need of many Middle income countries that
are not benefitting from GAVI support and are facing
challenges in the sustainable introduction of new and es-
sential vaccines. The project focuses on the provision of
accurate, reliable and neutral vaccine product, price and
procurement data, which are critical for the forecasting,
budgeting and sustainable financing of vaccines, yet cur-
rently not available for Middle income countries. The
intended output of the V3P project is an information
mechanism that allows for increased price transparency
and more informed decision making in the vaccine im-
plementation and procurement processes of Middle in-
come countries. One of the work streams of the project
included the review of six medicine price information
mechanisms to explore existing tools and lessons learned
through the operation of price information mechanisms:WHO’s Global Price Reporting Mechanism (GPRM) [21],
WHO/Health Action International’s (HAI) medicine price
database [22], Management Sciences for Health’s (MSH)
International Drug Price Indicator Guide [23], WHO/
Western Pacific Regional Office’s (WPRO) Price Informa-
tion Exchange (PIE) [24], the Global Fund’s Price and
Quality Reporting (PQR) tool [25], as well as Médicins
Sans Frontières’ (MSF) Untangling The Web (UTW) re-
port [26]. These mechanisms were selected to provide
information on best practices and lessons learned during
the set-up and operation that should inform a potential
vaccine price information mechanism envisioned by the
V3P project.
The review was conducted through direct test utilization
of the mechanisms and the examination of supporting
documents to learn about the mechanisms’ functionality
and their utility as data sources. Furthermore, 14 guided
semi-structured interviews were conducted with data
managers and other representatives of organizations
hosting these mechanisms in course of the V3P project
in 2011 and 2012 in order to learn about the evolution
of the mechanisms, challenges encountered, identified
best practices and user feedback. Certain findings of
this review are relevant for the debate on price trans-
parency and are presented in this article.
Results
Setup and functionality of the reviewed mechanisms
The six medicine price information mechanisms reviewed
for the V3P project include international price data with
five of the mechanisms also providing information on the
procurement modalities that resulted in the reported
prices. Table 1 provides an overview of the objective,
target audience and information provided by GPRM,
MSH’s Guide, PIE, PQR, UTW and WHO/HAI’s price
database.
All six mechanisms include the goal of increased price
transparency for their various target audiences in the
fields of policy making, public health budgeting or public
medicine procurement. With GPRM, the WHO/HAI data-
base and PIE, WHO has been directly involved in the
development and operation of three of these mechanisms.
Since 2000, WHO also collaborates with MSH on the
International Drug Price Indicator Guide.
Information provided
All mechanisms are publicly accessible and provide
information on product characteristics and pricing. With
the exception of WHO/HAI, the mechanisms also in-
clude information about procurement modalities real-
ized by national procurement agencies.
GPRM and PQR both contain transactional data of
medicines and other health products focusing on HIV/
AIDS, malaria and tuberculosis diagnosis and treatment.
Table 1 An overview of selected medicine price information mechanisms
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Table 1 An overview of selected medicine price information mechanisms (Continued)
UTW (MSF,
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and still shares similarities, although both mechanisms
have evolved differently. UTW, which is part of MSF’s
Campaign for Access to Essential Medicines, focuses on
Anti-Retroviral (ARV) medicines only. MSF considers
UTW a provider of complementary data to informa-
tion provided by GPRM and PQR.
Information sources
GPRM is built on a broad collaboration of several part-
ners and donors and is hosted at WHO. The mechanism
encourages competition and accountability of suppliers
and promotes benchmarking of supplier prices. Estab-
lished relationships with specific procurement agencies
as regular data providers allow GPRM to receive a con-
stant flow of data. One of GPRM’s data providers is the
Global Fund through its PQR mechanism. Data included
in the PQR is automatically fed into GPRMd. PQR
receives its information from Principal Recipients of
Global Fund support who are required to provide price
information following the receipt of goods purchased
with Global Fund support. These prices are used to
monitor the Principal Recipients and ensure that their
procurement concurs with Global Fund standards and is
within the international average price ranges.
UTW sources its information from ARV manufac-
turers who voluntarily provide price and procurement
information on an annual basis. This makes UTW the
only source of medicine price information reviewed
that includes information provided by pharmaceutical
suppliers to identify criteria for price differentiation
between buyers.
PIE, MSH’s Guide and WHO/HAI’s price database
contain a broader range of medicines. PIE provides com-
parative information on the procurement prices of se-
lected medicines that focus on common conditions and
are widely used by countries participating in the mech-
anism. The mechanism receives its data from member
states who voluntarily provide their price and procure-
ment information on an annual basis. MSH’s International
Drug Price Indicator database provides product, price and
procurement information on various health items, including
medicines that are registered in WHO’s Essential Medicines
List (EML). Data providers include NGOs, international
donor agencies, UN agencies and purchasing countries.
Unlike the other five mechanisms reviewed, WHO/
HAI collects its data from independent researchers who
conduct medicine price surveys according to the instruc-
tions outlined in WHO/HAI’s survey manuale. A typical
survey collects data on 50 medicines in six geographic or
administrative areas of a country and samples public health
facilities, registered private retail medicine outlets and up to
two other sectors in which medicines are commonly
assessed (such as the mission sector). In addition toproviding access to survey data, WHO/HAI provides
advice on national pricing policy options and gives in-
structions on the establishment of monitoring systems
through the WHO/HAI manual.
Depending on the type of data source, the reliability of
data comparison between countries may vary. Data col-
lected by mechanisms that source their information
from countries does not reveal the number of middle-
men and the amount of mark-ups included in the re-
ported price. More reliable results from medicine price
data comparisons between countries can be expected
from mechanisms that source their data directly from
the manufacturer (UTW), from international procure-
ment agents (GPRM), or from data sources with a
strong incentive to cut avoidable mark-ups (PQR and
the Principal Recipients of Global Fund support).
Data volume
GPRM and PQR handle large amounts of data every
year. Since their inception, GPRM and PQR have col-
lected around 70,000 and 35,000f entries of transaction
data, respectively. In comparison, MSH’s database pro-
vides product, price and procurement information on
more than 1,100 items, including health products other
than medicines. PIE provides information about 40 med-
icines purchased by 23 member states within WHO’s
Western Pacific Region; however, only for the years 2009
and 2010. The latest UTW reported price information
on 33 ARV medicines [27]. WHO/HAI depends on the
completion of individual country surveys to build its
database. To date, the WHO/HAI database provides
information on 400 entries of various presentations of
medicines from surveys conducted in 54 countries, with
individual countries being the focus of one or more of
these surveys.
Data collation
All mechanisms except UTW and WHO/HAI allow for
the automatic collation of medicine price data between
different countries and years. GPRM, PQR and PIE
break down price information into more detail and
thereby enable users to conduct additional price ana-
lyses. UTW is available in report format only and while
price developments of individual medicines over time
are depicted in charts, comparisons between years need to
be conducted manually between different reports. Inter-
national price comparisons conducted with WHO/HAI
data are limited to the availability of survey data for
specific countries and years.
The comparability of international medicine price data
requires certain modifications to account for differences
in purchasing power parity or inflation when comparing
across countries or years. The WHO/HAI manual [4] pro-
vides detailed instructions for the users of its database to
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meaningful data. MSH’s Guide indicates exchange rates
used for individual years and instructs its users to take
into account additional factors such as financing, procure-
ment modalities and supply chain peculiarities that may
influence price calculations. Data included in the GPRM,
PQR, PIE and UTW mechanisms are presented in USD as
indicated by the individual data providers which simplifies
collation but also inhibits the risk of potential calculation
errors made before the data reaches the database of the
information mechanisms.
Observed effects of medicine price information
mechanisms
Interviews conducted with data managers of the reviewed
price information mechanisms indicated certain market
effects that may be connected to the operation of some of
the mechanisms.
PIE learned from some of the countries participating
in the mechanism that they were able to negotiate more
favorable terms for their procurement contracts after
having had access to price information from other coun-
tries in Pacific region which paid significantly less for
their medicines. Similarly, a 2004 user survey conducted
by MSH indicated that almost half of the price compari-
sons conducted with information from the International
Drug Price Indicator Guide contributed to some form of
price savings. WHO/HAI observed changes in national
pricing policies that have resulted in lower prices in
Indonesia, Lebanon and elsewhere [4].
Mandatory reporting requirements applied to Principal
Recipients of the Global Fund most likely contributed to
an increased demand for high quality products. This
effect was observed by PQR data managers following the
introduction of compulsory reporting of price and pro-
curement details for all goods purchased with Global
Fund support to PQR. Although the Global Fund always
required the purchase of high quality products, the con-
stant and immediate monitoring of purchases through
the PQR triggered a significant increase in adherence to
procurement and supply management requirements and
an increase in efficiency.
Since its launch, UTW has achieved a lot of recogni-
tion on the ARV market, providing an incentive to man-
ufacturers of ARV drugs to voluntarily and regularly
provide price information to this annual price report.
The report now includes information from all major
ARV manufacturers that provide originator brands of
products recommended by WHO treatment guidelines.
The team working on MSF’s UTW mechanism observed
that prices for some of the generic ARV drugs included
in their report have decreased and converged over time.
This effect was observed particularly for medicines pro-
duced by more than three generic companies, whichincludes increased competition in addition to improved
price transparency as a potential cause of price de-
creases. Based on the experience with UTW, MSF notes
a positive effect of price transparency on increased
access to medicines.
Discussion
Established for varying target audiences, the reviewed
mechanisms respond to the need for more transparent
price information expressed by countries, donors and
various other entities. There is little data available on
how many countries are utilizing the reviewed mecha-
nisms. Still, there is continuing demand for medicine
price information. While not all of the reviewed informa-
tion mechanisms conduct systematic user evaluations,
MSH’s Guide, PIE and UTW receive positive feedback
from the users of their data. GPRM and PQR regularly re-
spond to user requests regarding their data and mechan-
ism. At the same time WHO/HAI continues to provide
technical support to researchers using WHO/HAI meth-
odology and receives requests to use the data in their
database. Following the launch of the manual, WHO/HAI
observed an unexpectedly high demand for training work-
shops on the methodology. To date, about 100 surveys
using WHO/HAI’s methodology have been completed or
are nearing completion.
The reviewed mechanisms allow for the comparison of
international medicine prices while avoiding methodo-
logical challenges observed for comparisons using only
national price databases as information sources. GPRM,
MSH’s Guide, PIE, PQR and UTW allow users to access
information on international medicine prices on a single
platform. Data is coherently collected with methodolo-
gies and procedures established by the individual mecha-
nisms. WHO/HAI enables price comparisons through
use of a standardized methodology and adjustment pro-
cedures that allow for the comparison of medicine prices
across countries and years. However, one needs to recognize
the caveat that all reviewed mechanisms still need to rely on
the accuracy of data received from their various sources,
over which they have little to no influence.
The majority of the reviewed mechanisms provide
some procurement information in addition to pricing
data, although to different extents. Such additional infor-
mation is important when conducting international price
comparisons, in order to understand prices in their indi-
vidual contexts and to determine the types and levels of
mark-ups included at different stages of the supply
chain. Compared to the other reviewed mechanisms,
GPRM and PQR offer the most detailed information on
procurement modalities accompanying the reported prices.
PIE provides detailed country profiles that present back-
ground information on regulations and procedures in place,
which enables a better interpretation of price information.
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individual contexts and UTW provides terms of access to
certain prices for specific purchasers. WHO/HAI does not
provide information on procurement modalities.
Focus on ARV prices
GPRM, PQR and UTW focus on HIV/AIDS related
medicines (with GPRM and PQR also including infor-
mation on malaria and tuberculosis medicines and re-
lated products). The amount of price information available
for ARV medicines and other health products focusing on
HIV/AIDS is remarkable and may reflect the prominence
of HIV/AIDS on the international health agenda over the
past decade.
Other increasingly important pharmaceutical segments
have not seen the establishment of similar mechanisms
with a specific focus. For example, in some Low income
and Middle income countries the cost of drugs treating
chronic diseases can represent a significant share of pub-
lic and private medical expenditures [28]. The successful
operation of price information mechanisms focusing on
HIV/AIDS medicines may provide an incentive for simi-
lar tools to be implemented, that focus on other import-
ant diseases and public health cost drivers.
The focus on ARV prices of some of the observed
mechanisms may also have contributed to the decline of
prices of certain medicines reported by data managers.
In addition to UTW, the data managers of GPRM and
PQR observed similar developments occurring during
the operation of price information mechanisms focusing
on ARV prices and other products. Nevertheless, these
price declines may be due to a variety of causes, poten-
tially including increased price transparency. For ex-
ample, a strong donor focus and the availability of donor
funds [29] created a considerably large and risk-free
environment that sets aside ARV from other medicine
markets. Additional research would be necessary before
drawing any definite conclusions on the causes of the
price decreases observed.
Potential benefits of medicine price information
mechanisms
Medicine price information mechanisms contribute to
increased price transparency by allowing users to com-
pare prices, understand the composition of these prices
and provide better insights into existing procurement
systems. Access to increased information can contribute
to cost savings and potentially increase the access to
medicines for developing countries. In addition to the
extraction of price data, the utilization of medicine price
information mechanisms may also help countries gain a
better understanding of the different components in-
volved in medicine procurement. One important lesson
learned from PIE’s experience is that participating countriesvoluntarily shared their price and procurement information
with other countries providing information to the mechan-
ism. This allowed them to evaluate their procurement pro-
cedures and compare them to the systems used by other
countries.
In order to derive the highest possible benefits from
improved price transparency, countries first need to be
aware of the existence of tools providing detailed price
information. Raised awareness could help increase the
utilization of price information mechanisms. Further-
more, clear instructions and user support regarding the
most effective utilization of the mechanisms and the
correct interpretation of data are necessary to achieve
meaningful results. Finally, depending on the need of
individual countries, targeted capacity building can help
maximize the effects derived from increased information
and help improve the access to medicines for developing
countries.
Conclusion
Working with accurate and contextually rich data, medi-
cine price information mechanisms have the potential to
play an important role in making medicines prices more
transparent. Positive user feedback and ongoing data
requests received by the reviewed mechanisms indicate a
high demand for increased medicine price transparency.
Taking into account the amount of information gathered
and accessed by mechanisms that focus on medicines
and health products related to HIV/AIDS, malaria and
tuberculosis, it would be interesting to see whether and
to what extent mechanisms focusing on different disease
segments could encounter a similar demand. Market im-
pact assessments exploring the effects of dedicated donor
funds may help explain the driving force of user demands.
The divergent views on whether increased medicine
price transparency generates more value or harm to the
availability and affordability of medicines in developing
countries need to be considered within the context of
individual medicines. From a theoretical point of view, the
effects of increased price transparency are highly dependent
on the degree of competition prevalent in a market. Prac-
tically speaking, this requires more detailed analyses of
different groups of medicines, depending on the maturity
of their market.
Additional research would also be necessary to provide
more clarity on the extent of which the information and
data provided by the reviewed price information mecha-
nisms contributes to price decreases and other market
effects. Information gathered during the review of the
six medicine price information mechanisms derives from
user statements and observations made by data man-
agers on price developments over time. Longitudinal
studies building on market analyses and targeted user
evaluations may help produce more significant data that
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mechanisms on medicine suppliers and purchasing
countries.
Nevertheless, as demonstrated through the informa-
tion provided by the interviewees, the review of the
mechanisms did reveal positive effects on the behavior
of their users. While the cause(s) of the observed re-
duced procurement costs for ARV and other medicines
still need to be fully determined, countries using the PIE
mechanism were able to negotiate more favorable prices
for their medicines. Also, the utilization of the PQR
mechanism led to the procurement of better quality
medicines.
Taking into account these positive effects for developing
countries and their health systems, the operation and
utilization of medicine price information mechanisms
should be encouraged and supported where needed.
Endnotes
aFollowing the target audience of the medicine price
information mechanisms discussed in this article, the
authors chose the term “developing countries” to include
all countries not defined as High income countries follo-
wing the World Bank Atlas method (GNI < USD 12,615
per year).
b2 out of 36 Low income countries and 17 out of 54
Lower middle income countries (using the World Bank
Atlas method).
cVan Dongen’s analysis focused on the medicine
prices of seven of the 14 medicines collected globally in
WHO/HAI surveys.
dWhen this article was written, GPRM only contained
data about HIV/AIDS related products, with information
about malaria and tuberculosis related medicines and
health products undergoing quality control.
eThe WHO/HAI survey methodology has been pub-
lished as a manual with an accompanying automated
Excel workbook for data entry and analysis. The metho-
dology’s second edition was published in 2008.
fThe currently available upgraded version of PQR
contains about 20,000 entries.
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